Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Knudsen, Niels Peter H ^a   Olsen, Anja ^a   Buonsanti, Cecilia ^b   Follmann, Frank ^a   Zhang, Yuan ^c   Coler, Rhea N ^d   Fox, Christopher B ^d   Meinke, Andreas ^e   Dóro, Ugo ^b   Casini, Daniele ^b   Bonci, Alessandra ^b   Billeskov, Rolf ^a   De Gregorio, Ennio ^b   Rappuoli, Rino ^b   Harandi, Ali M ^c   Andersen, Peter ^a   Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^e Valneva Austria GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ANIMAL; ANTIBODY SPECIFICITY; CELLULAR IMMUNITY; CHLAMYDIA INFECTIONS; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; TUBERCULOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS; CHLAMYDIA INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LYMPHOCYTES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; TUBERCULOSIS; VACCINATION; VACCINES;

EID: 84955611006     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19570     Document Type: Article

References (69)

1. Giefing, C. et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med. 205, 117-131 (2008).
2. Rappuoli, R., Pizza, M., Del Giudice, G. & De Gregorio, E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA 111, 12288-12293 (2014).
3. Dorrington, M. G. & Bowdish, D. M. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 4, 171 (2013).
4. Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 182, 8047-8055 (2009).
5. Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med. 2, 15ra15 (2010).
6. Dietrich, J., Andreasen, L. V., Andersen, P. & Agger, E. M. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One. 9, e100879 (2014).
7. Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 9, 287-293 (2009).
8. van Dissel, J. T. et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine. 28, 3571-3581 (2010).
9. van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 32, 7098-7107 (2014).
10. Harandi, A. M., Davies, G. & Olesen, O. F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines. 8, 293-298 (2009).
11. Redford, P. S. et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol. 40, 2200-2210 (2010).
12. Peng, Y. et al. Interleukin-22 promotes T helper 1 (Th1)/Th17 immunity in chlamydial lung infection. Mol Med. 20, 109-119 (2014).
13. Ohmit, S. E., Petrie, J. G., Cross, R. T., Johnson, E. & Monto, A. S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 204, 1879-1885 (2011).
14. Follmann, F. et al. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J Infect Dis. 197, 897-905 (2008).
15. Agger, E. M. et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 3, e3116 (2008).
16. Aagaard, C. et al. Protection and polyfunctional T cells induced by Ag85B-TB10. 4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One. 4, e5930 (2009).
17. Windish, H. P. et al. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine. 29, 7842-7848 (2011).
18. Davidsen, J. et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. Tuberculosis (trehalose 6, 6?-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718, 22-31 (2005).
19. Calabro, S. et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 31, 3363-3369 (2013).
20. Hekele, A. et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2, e52 (2013).
21. Hoang, T. et al. ESAT-6 (EsxA) and TB10. 4 (EsxH) based vaccines for pre-and post-exposure tuberculosis vaccination. PLoS One. 8, e80579 (2013).
22. Lindenstrom, T., Knudsen, N. P., Agger, E. M. & Andersen, P. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells. J Immunol. 190, 6311-6319 (2013).
23. Lindenstrom, T. et al. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun. 80, 3533-3544 (2012).
24. Caproni, E. et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol. 188, 3088-3098 (2012).
25. Orr, M. T. et al. Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis. J Immunol. 193, 2911-2918 (2014).
26. Geeraedts, F. et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses. 2, 41-51 (2008).
27. Daifalla, N. S., Bayih, A. G. & Gedamu, L. Immunogenicity of Leishmania donovani iron superoxide dismutase B1 and peroxidoxin 4 in BALB/c mice: the contribution of Toll-like receptor agonists as adjuvant. Exp Parasitol. 129, 292-298 (2011).
28. O'Meara, C. P. et al. Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS One. 8, e61962 (2013).
29. Goff, P. H. et al. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One. 8, e79194 (2013).
30. Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 8, 247-258 (2008).
31. Fabbiani, M. et al. HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. Vaccine. 31, 2914-2918 (2013).
32. Galli, G. et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA. 106, 3877-3882 (2009).
33. Zedda, L. et al. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. Pediatr Infect Dis J. 34, 73-78 (2015).
34. Ott, G., Barchfeld, G. L. & Van Nest, G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. 13, 1557-1562 (1995).
35. Vesikari, T. et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 365, 1406-1416 (2011).
36. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat Med. 19, 1597-1608 (2013).
37. Galli, G. et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA. 106, 7962-7967 (2009).
38. Davenport, F. M., Hennessy, A. V. & Askin, F. B. Lack of adjuvant effect of AlPO4 on purified influenza virus hemagglutinins in man. J Immunol. 100, 1139-1140 (1968).
39. Tetsutani, K. & Ishii, K. J. Adjuvants in influenza vaccines. Vaccine. 30, 7658-7661 (2012).
40. Bernstein, D. I. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 197, 667-675 (2008).
41. O'Hagan, D. T., Rappuoli, R., De Gregorio, E., Tsai, T. & Del Giudice, G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines. 10, 447-462 (2011).
42. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 19, 1305-1312 (2013).
43. Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 18, 274-280 (2012).
44. Clegg, C. H. et al. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci USA. 109, 17585-17590 (2012).
45. Treanor, J. J. et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+ GLA) adjuvant. Vaccine. 31, 5760-5765 (2013).
46. Martel, C. J. et al. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS One. 6, e22891 (2011).
47. Riedl, K., Riedl, R., von Gabain, A., Nagy, E. & Lingnau, K. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine. 26, 3461-3468 (2008).
48. Schellack, C. et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 24, 5461-5472 (2006).
49. Christensen, D. et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release. 160, 468-476 (2012).
50. Vogelzang, A. et al. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis. J Infect Dis. 210, 1928-1937 (2014).
51. Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. 187, 2222-2232 (2011).
52. Schoenen, H. et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol. 184, 2756-2760 (2010).
53. Flornes, L. M. et al. Identification of lectin-like receptors expressed by antigen presenting cells and neutrophils and their mapping to a novel gene complex. Immunogenetics. 56, 506-517 (2004).
54. Ostrop, J. et al. Contribution of MINCLE-SYK Signaling to Activation of Primary Human APCs by Mycobacterial Cord Factor and the Novel Adjuvant TDB. J Immunol. 195, 2417-2428 (2015).
55. Brunham, R. C. et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis. 173, 950-956 (1996).
56. Igietseme, J. U. et al. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol. 5, 317-324 (1993).
57. Yu, H. et al. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect Immun. 78, 2272-2282 (2010).
58. Hawkins, R. A., Rank, R. G. & Kelly, K. A. A Chlamydia trachomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa. Infect Immun. 70, 5132-5139 (2002).
59. Olsen, A. W., Follmann, F., Erneholm, K., Rosenkrands, I. & Andersen, P. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J Infect Dis. 212, 978-989 (2015).
60. Morrison, R. P., Feilzer, K. & Tumas, D. B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun. 63, 4661-4668 (1995).
61. Balu, S. et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 186, 3113-3119 (2011).
62. Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 82, 488-496 (2004).
63. Centers for Disease Control and Prevention. Vaccine excipient and media summary in Epidemiology and prevention of vaccinepreventable diseases. 13th edn (eds J. Hamborsky, A. Kroger & S. Wolfe) App. B-7 (Centers for Disease Control and Prevention, 2015).
64. Podda, A. & Del Giudice, G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2, 197-203 (2003).
65. El Sahly, H. MF59™ ; as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 9, 1135-1141 (2010).
66. O'Hagan, D. T., Ott, G. S., De Gregorio, E. & Seubert, A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine. 30, 4341-4348 (2012).
67. Coler, R. N. et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One. 5, e13677 (2010).
68. Werninghaus, K. et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med. 206, 89-97 (2009).
69. Agger, E. M. et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine. 24, 5452-5460 (2006).